This is relevant because immunotherapy as a second-line treatment has shown an attenuated efficacy in patients with a negative PD-L1, in those with rapidly progressive disease, in women, and in nonsmokers.32,36. This evidence concerns the gene CD274 and glycogen storage disease VI.